Best Practices in the Management of Hypertension in Older Adults
|
|
- Cory Hoover
- 6 years ago
- Views:
Transcription
1 Best Practices in the Management of Hypertension in Older Adults George Dresser, MD, PhD, FRCPC Associate Professor of Medicine Division of Clinical Pharmacology, Western U.
2 Speaker Disclosure Form George Dresser I have had in the past 2 years, a financial interest, arrangement or affiliation with one or more organizations that could be perceived as a direct/indirect conflict of interest in the content of the subject of this or any other program. 1. Grant / Research Support Abbott, Boehringer Ingelheim, Heart and Stroke Foundation Ontario, Merck 2. Speaker s Honorarium Abbott, Astra, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Novartis, Pfizer, and Servier
3 Workshop objectives 1. Discuss the rationale for changing blood pressure targets and optimal anti-hypertensive medications 2. Describe an approach to orthostatic hypotension
4 Proportion of Deaths Attributable to Leading Risk Factors Worldwide (2000) Attributable Mortality WHO 2000 Report. Lancet. 2002;360:
5 Annual rate/1000 OXVASC community-based acute stroke and acute MI CAD CVD Rothwell PM et al. Lancet 2005
6 Risk factors for stroke Risk vs prevalence Hypertension 35% Hyperlipidaemia 27% Smoking 27% Percentages indicate prevalence Inactivity 27% Obesity 18% Carotid stenosis 4% Atrial fibrillation 2% Alberts. Curr Med Res Opin 2003;19: Relative risk
7 Impact of Risk factors on Stroke Risk Prevalence % Pop. AR % Relative Risk Factor Hypertension Age 50 y Age 60 y Age 70 y RRR 38% Smoking % Diabetes % Obesity Unknown Goldstein et al. AHA/ASA Guideline: Primary Prevention of Ischemic Stroke. Circulation.2006; 113: e873-e923doi: /
8 Case #1 70 yo male patient new to your practice. Presents because his blood pressure was noted to be 168/80 in the pharmacy His wife just had a stroke and is in Rehab He is asymptomatic He has no history of CV end organ damage Age of onset was likely ~ 50, no obvious secondary causes On no medications Seems motivated
9 Case #1 BP History Step 1: Is he symptomatic from hypertension? o Confusion o Headache o Dyspnea/CHF o Chest pain Step 2: Does he have secondary hypertension? Step 3: What can he do non-pharmacologically to help control his BP? o Salt reduction strategies o Exercise strategies o Everything else Step 4: Compelling reasons for specific pharmacotherapy
10 Case #1 BP Physical Step 1: Evaluate BP o In clinic: Both arms, orthostatic, and possibly the legs o Pattern assessment: repeat clinic, versus HBPM, versus ABPM Step 2: Assessment of target organ damage? o Cognitive impairment, PRES, stoke o Retinopathy o Vascular disease o LVH o Endocrine hypertension
11 Consider aggravating causes 2 Causes Self-inflicted Doctor-inflicted: Fate Salt Wear a white Obstructive coat (or make sleep apnea patients wait) (mimics pheo/1 Aldo biochemically) NSAIDs Not measure Consider BP correctly Hyperaldosteronism (single in those Stimulants (Street drugs/otc) measurements with/without are not low serum [K] Alcohol adequate) Intrinsic kidney disease Withdrawal reactions Give from drugs: (do a urinalysis for both blood and prescription or non-prescription Glucocorticoids drugs protein or microalbumin/cr ratio) Pain Stimulants Consider RAS in those with NSAIDs atherosclerosis Estrogens/Androgens Thyroid/Parathyroid disease Cyclosporine/EPO (measure TSH and a serum [Ca]) Nasal decongestants Consider other endocrine causes (Pheo, Cushings, Acromegaly, etc)
12 Back to the Case 70 yo male BP /80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Appears to be 1 Hypertension Working at salt reduction Exercise 30 min/day Why give him BP drugs? What is your goal? Can you do this safely? What drugs should you use? What is the evidence they work? How many will he need? How should they be followed up?
13 How I talk to the patient about BP Drugs 70 yo male BP /80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day If we get you on the right pills, and they successfully lower your BP, we can lower your risk of stroke by half, prevent heart failure, and make your life in the future better. My goal is that you get this benefit while feeling well and experiencing no side effects. I will worry about the side effects, so you don t have too.
14 What is the target BP? 70 yo male BP /80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Is there an optimal BP? 130/80?? Is there an optimal drop in BP? -20/-10?? Is the BP/Benefit curve J-shaped? Harm at the lowest levels?? Should we target the systolic, or the diastolic BP, or both??
15 Evidence-based Annual Recommendations The Canadian Hypertension Education Program is central to Hypertension Canada CHEP is known as the most credible source for evidence-based chronic disease management recommendations with annual updates, a well-validated review process and effective dissemination techniques across Canada Canada has the world s highest reported national blood pressure control rates
16 CHEP 2013 Committee
17 The HYpertension in the Very Elderly Trial N. Beckett, R. Peters, A. Fletcher, C. Bulpitt on behalf of the HYVET committees and investigators ClinicalTrials.gov: NCT
18 HYVET Blood pressures BP throughout trial BP target group Active Placebo SBP (mm Hg) Baseline Achieved Difference DBP (mm Hg) Baseline Achieved Difference 13 7 Lancet May 30; 373(9678):
19 Blood Pressure (mmhg) Blood pressure separation mmhg Median follow-up I 1.8 years Follow-up (years) 6 mmhg Placebo Indapamide SR +/- perindopril
20 All stroke (30% reduction) No. at Risk Placebo IndapamideSR perindopril
21 Total Mortality (21% reduction) No. at Risk Placebo IndapamideSR perindopril
22 Heart Failure (64% reduction) No. at Risk Placebo IndapamideSR perindopril
23 HYVET Conclusions In a group of patients with an initial mean age of 84 and BP of 173/91, targeting an SBP < 150, and achieving a BP of 143/78, resulted in substantially better outcomes than if achieved BP is 158/84 Addition of a simple diuretic/acei combination drug to Very Elderly patients prevented problems they care about: o Heart Failure: You will end up spending hours in ER with puffy legs and the oxygen hose in your nose o Stroke o Death
24 Japanese Trial to Assess Optimal Systolic Blood pressure in Elderly Designed to compare target SBP < 140 to a target of Japanese patients with 1 HTN and age enrolled in PROBE design Mean baseline blood pressure 172/89 Mean age 74 Average follow up 2 years Hypertens Res 2008; 374:
25 JATOS Primary outcome Hypertens Res 2008; 374:
26 JATOS conclusions Patients aged (mean 74) with a baseline BP of 172/89 down to did equally well if their BP was lowered to 146/78 or 136/75 Patients under the age of 75 seemed to be better if assigned to strict control, and those over the age of 75 seemed better if assigned to mild (Hyvet style) treatment Rates of 1 Outcome Hypertens Res 2008; 374:
27 BP treatment in the elderly Rule out significant orthostatic BP drop If patient is over age 80, target SBP<150 If patient is under age 75, target SBP<140
28 CHEP Recommendation: the very elderly III. Choice of Therapy for Adults With Hypertension without Compelling Indications for Specific Agents B) Recommendations for Individuals with Isolated Systolic Hypertension New Recommendation for 2013 ADD: In the very elderly (age 80 years and older), the target for systolic BP should be < 150 mmhg (Grade C).
29 Back to the Case 70 yo male BP /80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Why give him BP drugs? What is your goal? Can you do this safely? What drugs should you use? What is the evidence they work? How many will he need? How should they be followed up?
30 Studies of BP Drugs in the Elderly Drug Class Thiazide diuretics CCB-DHP ARB ACE-I Study SHEP, HYVET Syst-Eur MOSES, LIFE HYVET, ANBP
31 Case Conclusion 70 yo male BP /80-85 repeated measures No postural drop Asymptomatic Borderline LVH on ECG No other comorbidities Working at salt reduction Exercise 30 min/day Given that BP is > 20 mm Hg above target, he will require 2 or 3 medications My option A (No concerns about CHF or leg edema): o Start with ARB/DHP combination, half dose o If necessary add half dose diuretic My option B: o Start with ARB/ACEi in combination with diuretic o Add DHP if necessary
32 Case 2 80 yo male Coming home from hospital after 3 rd bad fall this year broken pelvic bone Note from medical student at hospital: He had hypertension throughout hospitalization which was attributed to pain please reassess in clinic His clinic BP s recorded 3 times over last year 135/68, 146/72, 138/70 Today it is 138/68 Two years ago another doctor tried him on amlodipine 5 mg daily he felt rotten and stopped it. He describes excessive nocturia
33 Case 2 80 yo male 3 rd bad fall this year Hypertension in hospital Clinic BPs /68-72 Has DM2 with mild neuropathy Taking amitriptyline 10 mg qhs and terazosin for urination Has excessive nocturia What should you do: 1. Consult psychogeriatrics 2. Consult geriatrics 3. Refer to Dr. Dresser 4. Move your office so it is up one flight of stairs 5. Cancel the rest of your clinic and do a proper assessment of postural BPs
34 80 yo male 3 rd bad fall this year Hypertension in hospital Clinic BPs /68-72 Has DM2 with mild neuropathy Taking amitriptyline 10 mg qhs and terazosin for urination (both started recently in hospital) Patient describes excessive nocturia Case 2 After lying supine for 5 minutes, blood pressure is recorded at 184/80 After sitting for 1 minute, BP is 138/68 After standing 1 minute, BP is 104/60 After standing 3 minutes, patient collapses with BP recorded at 94/58
35 ASH Position Paper: Evaluation and Treatment of Orthostatic Hypotension The Journal of Clinical Hypertension Volume 15, Issue 3, pages , 14 JAN 2013 DOI: /jch
36 The American Journal of Medicine, Vol 120, No 10, October 2007, pp
37 Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia What are the goals of treatment in this man? What causes him to have nocturia? What are you more afraid of?: o Supine Grade III HTN o Standing hypotension Is it possible treat both the hypertension and the hypotension simultaneously?
38 Non-Drug Management Orthostatic Hypotension Withdraw offending medication (either substitution or discontinuation) Rise slowly from supine to sitting to standing position Avoid straining, coughing, and prolonged standing in hot weather Cross legs while standing Squat, stooping forward Raise head of bed 10 to 20 degrees Small meals and coffee in the morning Elastic waist high stocking Increase salt and water intake Exercise, eg, swimming, recumbent biking, and rowing The American Journal of Medicine, Vol 120, No 10, October 2007, pp
39 Management of Supine Hypertension/Nocturesis Raise head of bed 10 to 20 degrees Short acting antihypertensive at bed-time o Clonidine o Captopril Commode at bedside to avoid upright posture when lights are turned down/off
40 Drugs for Orthostatic Hypotension Drug Dose Contraindication Common Side Effects Fludrocortisone Midodrine Initial: 0.1 mg daily Max.: 1 mg daily Initial: 2.5 mg tid Max.: 10 mg tid Hypersensitivity IHD, CHF, urinary retention, thyrotoxicosis, acute renal failure Ibuprofen mg tid Hypersensitivity to NSAIDs, active bleeding, impaired renal function Supine hypertension, hypokalemia, HF, headache Supine hypertension, piloerection, pruritus, paresthesia GI intolerance, bleeding, headache, dizziness, renal insufficiency Caffeine mg daily Hypersensitivity GI irritation, I nsomnia, agitation,nervousness Erythropoietin U/Kg tiw Uncontrolled hypertension Stroke, myocardial infarction, hypertension
41 Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! Step 1: Stop amitriptyline Step 2: Stop terazosin Step 3: Head of bed under 1 or 2 bricks Step 4: Compression stockings thigh/waist high Step 5: Clinically reassess +/- ABPM
42 Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! Step 6: If volume status low, fludrocortisone or water/salt Step 7: If volume up, Caffeine, then midodrine q4h prn while planning to be up must not take within 4 hours of being upright
43 Back to Case 2 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Goal: Improve Function! If omidodrine 10 mg TID Then ocall CMPA Midodrine should not be prescribed without careful instructions about how to use safely
44 80 yo male 3 rd bad fall this year Supine Hypertension Standing Hypotension DM2 with neuropathy amitriptyline 10 mg qhs for neuropathy terazosin for urination Excessive nocturia Back to Case 2 Goal: Improve Function! If ABPM shows significant supine hypertension Then start clonidine 0.1 to 0.4mg qhs o Monitor nocturia o Alternate: Captopril mg qhs All antihypertensives should be given at bed time!!
45 Workshop objectives 1. Discuss the rationale for changing blood pressure targets and optimal anti-hypertensive medications 2. Describe an approach to orthostatic hypotension
Hypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationApproach to patient with hypertension. Dr. Amitesh Aggarwal
Approach to patient with hypertension Dr. Amitesh Aggarwal Definition A systolic blood pressure ( SBP) >139 mmhg and/or A diastolic (DBP) >89 mmhg. Based on the average of two or more properly measured,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationDisclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012
How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D.,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationSystemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept
Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Continents 1- introduction 2- classification/definition 3- classification/etiology 4-etiology in both categories 5- complications
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationDiagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study
Diagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study Learning Objectives: Illustrate how to accurately diagnose noh Employ scales and questionnaires in combination with cardiovascular
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationObjective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel
Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationNew Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationNew Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine
New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationHypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to
Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationGenetic factors. A number of genetic factors or interactions between genes play a major role in essential hypertension.
Hypertension Blood pressure is a measurement of the force against the walls of your arteries as your heart pumps blood through your body. Hypertension is another term used to describe high blood pressure.
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationUpdate on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta
Update on HTN and ABPM Raj Padwal Division of General Internal Medicine University of Alberta Disclosures Funding: CIHR, AIHS, HSF, UHF Research Collaboration: Novo Nordisk, CVRx Consulting: Vivus, Medtronic
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationHypertension and Diabetes Will Controversies Help Our Patients? Insights of JNC Report Jorge De Jesús MD FACE
Hypertension and Diabetes Will Controversies Help Our Patients? Insights of JNC8 2013 Report Jorge De Jesús MD FACE Disclosures Dr Jorge De Jesús has received honorariums as speaker for the following pharmaceutical
More informationFrom the desk of the: THE VIRTUAL NEPHROLOGIST
Hypertension, also referred to as high blood pressure or HTN, is a medical condition in which the blood pressure is chronically elevated. It is a very common illness. One out of three American adults has
More informationPharmacologic Management of Hypertension
Current Concepts In Management of Fernando Vega, MD Secondary - Definition Renovascular Disease (The kidney doesn t get impressed by blood pressure) Renovascular stenosis Renal artery stenosis Fibromuscular
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationImplementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care
Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care Shari Bolen MD, MPH MetroHealth/Case Western Reserve University 1 Disclosure
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationWhat is hypertension?
HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90
More information